CD27 in B-cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily

Haematologica

Volumn 83, Issue 5, 1998, Pages 398-402

  Molica, Stefano ^a   Vitelli, Gaetano ^b   Levato, Domenico ^a   Crispino, Giulino ^a   Dell'Olio, Matteo ^c   Dattilo, Angela ^a   Matera, Rosella ^c   Gandolfo, Giuseppe Maria ^b   Musto, Pellegrino ^c  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

APO 1 Fas; CD27; Chronic lymphocytic leukemia; TNF

Indexed keywords

CD27 ANTIGEN; CD5 ANTIGEN; NERVE GROWTH FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN SECRETION;

AGED; ANTIGENS, CD27; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; MULTIGENE FAMILY; RECEPTORS, NERVE GROWTH FACTOR; SOLUBILITY;

EID: 0031807584     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas. Blood 1995; 85:3378-404.
2. Maurer D, Holter W, Madjic O, Fischer GF, Knapp W. CD27 expression by a distinct subpopulation of human B lymphocytes. Eur J Immunol 1990; 20:2678-83.
3. van Oers MHJ, Pals ST, Evers LM, et al. Expression and release of CD27 in human B-cell malignancies. Blood 1993; 82:3430-6.
4. Caligaris-Cappio F. B-chronic lymphocytic leukemia: A malignancy of anti-self B cells. Blood 1996; 87:2615-20.
5. Cheson BD, Bennet JM, Crever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87:4990-7.
6. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48:198-206.
7. Rozman C, Montserrat E, Rodriguez-Fernandez JM, et al. Bone marrow histologic pattern. The best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases. Blood 1984; 64:642-8.
8. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL Leukemia 1994, 8:1640-5.
9. - B-cell lymphoid leukemias. Haematologica 1997; 82:553-7.
10. Molica S, Levato D, Dell'Olio M, et al. Cellular expression and serum circulating levels of soluble CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis. Haematologica 1996; 81:428-33.
11. Molica S, Levato D, Cascavilla N, et al. Combined effect of increased levels of beta-2 microglobulin and soluble CD23 in B-cell chronic lymphocytic leukemia. Blood 1997; 90(Suppl 1):523a.
12. Younes A, Consoli U, Zhao S, et al. CD3o ligand is expressed on resting normal and malignant B lymphocytes. Br J Haematol 1996; 93:569-71.
13. Levabre-Bertrand T, Janossy G, Exbrayat C, Bourquard P, Duperray C, Navarro M. Leukemia associated changes identified by quantitative flow cytometry: II. CD5 over-expression and monitoring in B-CLL Leukemia 1994; 8:402-8.
14. 2M) level is more powerful than stage in predicting response and survival of chronic lymphocytic leukemia (CLL). Blood 1995; 86(Suppl 1):606a.
15. Kato K, Kipps TJ. Metalloprotease inhibitors block the release of CD27 from chronic lymphocytic leukemia B cells. Blood 1997; 90(Suppl. 1):355a.
16. Foa R, Massaia M, Cardona S, et al. Production of tumor necrosis factor-α by B-cell cheonic lymphocytic leukemia cells: A possible regulatory role of TNF in the progression of the disease. Blood 1990; 76:393-400.
17. Panayiotidis P, Ganeshaguru K, Foroni L, Hoffbrand AV. Expression and function of the Fas antigen in B cell chronic lymphocytic leukemia. Leukemia 1995; 9: 1227-32.
18. Knipping E, Debatin KM, Stricker K, Heilig B, Eder A, Krammer PH. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood 1995; 85:1562-9.
19. Munker R, Midis G, Owen-Schaub L, Andreff M. Soluble Fas (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. Leukemia 1996; 10: 1531-3.
20. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263:1759-62.
21. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand CD70, on chronic lymphocytic leukemia B cells. Blood 1995; 85:3556-65.